INVENTOR SEAPCH

L7

```
=> fil casre; d que nos 130
FILE 'CASRRACT' ENTERED AT 11:19:12 ON 13 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT: 1840 - 8 Dec 2007 VOL 147 ISS 25

STR

New CAS Information Use Policies, enter HELP USAGETERMS for details.

```
* CASREACT now has more than 13.8 million reactions * *
```

Some CASREACT records are derived from the ZIC/VINITI database (1974-1999) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
L10
              STR
              STR
L12
              STR
T-13
              STR
L14
              STR
L15
L18 1017 SEA FILE=CASREACT SSS FUL (L10 OR L11 OR L12 OR L13 OR L14 OR
              L15) NOT L7 ( 7766 REACTIONS)
          957 SEA FILE=CASREACT ABB=ON L18/COMPLETE
L19
L21
          29 SEA FILE=CASREACT ABB=ON SHCHERBAKOVA I?/AU
L22
            0 SEA FILE=CASREACT ABB=ON BALANDRIA M?/AU
1.23
          101 SEA FILE=CASREACT ABB=ON HUANG G?/AU
L24
            5 SEA FILE=CASREACT ABB=ON GEOFFROY O?/AU
L25
          116 SEA FILE=CASREACT ABB=ON FOX J?/AU
L26
           50 SEA FILE=CASREACT ABB=ON NAIR S?/AU
L29
             7 SEA FILE=CASREACT ABB=ON BALANDRIN M?/AU
1.30
            3 SEA FILE=CASREACT ABB=ON (L21 OR L22 OR L23 OR L24 OR L25 OR
              L26 OR L29) AND L19
```

=> d ibib abs fhit 130 1-3

```
L30 ANSWER 1 OF 3 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 143:59927 CASREACT Full-text

TITLE: Design, new synthesis, and calcilytic activity of substituted 3H-pyrimidin-4-ones

AUTHOR(S): Shcherbarova, Irina; Huang, Guangfei ; Geoffroy, Otto J.; Nair, Satheesh
```

K.; Swierczek, Krzysztof; Balandrin, Manuel

F.; Fox, John; Heaton, William L.;

Conklin, Rebecca L.

CORPORATE SOURCE: Drug Discovery, NPS Pharmaceuticals, Inc., Salt Lake City, UT, 84108, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2005),

15(10), 2537-2540

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal LANGUAGE: English

LANGUAGE: GI

AB Design, synthesis, structure-activity relationship studies and calcium receptor antagonist (calcilytic) properties of 3H-pyrimidin-4-ones, e.g., I, are described. The pyrimidinones were synthesized by multistep procedures.

RX(80) OF 424 ... CV ===> DH

DH YIELD 70%

```
RX(80) RCT CV 780771-39-3
RGT U 1310-58-3 KOH
PRO DH 780771-35-9
```

SOL 7732-18-5 Water, 64-17-5 EtOH CON 12 hours, reflux

CON 12 hours, reflux

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 2 OF 3 CASREACT COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 141:379934 CASREACT Full-text

TITLE: Preparation of 2,3,5,6-tetrasubstituted

3H-pyrimidin-4-ones via cyclization of carboxamides.

INVENTOR(S): Shcherbakova, Irina; Balandrin, Manuel; Huang, Guangfei; Geoffroy, Otto; Foz, John; Nair, Satheash K.

PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

1				ND	DATE			Al	PPLI	CATI	ON N	Э.	DATE						
			A2 20041028 A3 20050414		W	WO 2004-US10639			20040407										
		W:	CN, GE,	CO, GH,	CR, GM,	CU, HR,	CZ, HU,	DE, ID,	DK, IL,	DM, IN,	DZ, IS,	EC, JP,	EE, KE,	EG, KG,	BY, ES, KP, MX,	FI, KR,	GB, KZ,	GD, LC,	
		RW:	NO, TJ,	NZ, TM,	OM, TN,	PG, TR,	PH, TT,	PL, TZ,	PT, UA,	RO, UG,	RU, US,	SC, UZ,	SD, VC,	SE, VN,	SG, YU, ZM,	SK, ZA,	SL, ZM,	SY, ZW	
			ES,	FI.	FR,	GB,	GR,	HU,	IE,	IT,	LU,	MC,	NL,	PL,	CZ, PT, ML,	RO,	SE,	SI,	
1	EP	1613 R:	606 AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	2004 NL,	SE,			
		2006 2007	5221	60	T		2006	0928		J! U:	P 20 S 20	06-5 06-5	0975 5192	9	2006	0407 1120	PL,	SK,	HR
PRIOR	ITY	APP.	LN.	INFO	.:					U	S 20	03-4	7932	3P	2003 2003 2004	0618			

AB The title process is claimed. Thus, 3-(2-acetoxybenzoylamino)-2-methylbut- 2-enoic acid phenethylamide (preparation given) was refluxed overnight with KOH in EtOH/H2O to give 37% 2-(2-hydroxyphenyl)-5,6-dimethyl-3-phenethyl-3H-pyrimidin-4-one.

MARPAT 141:379934

RX(2) OF 57 ...G ===> H

OTHER SOURCE(S):

(2)

RCT G 780771-39-3 RX(2)

STAGE (1)

RGT I 1310-58-3 KOH

SOL 7732-18-5 Water, 64-17-5 EtOH CON SUBSTAGE(1) overnight, reflux

SUBSTAGE(2) cooled

STAGE(2)

RGT D 7647-01-0 HC1 SOL 7732-18-5 Water

CON pH 1

PRO H 780771-35-9

L30 ANSWER 3 OF 3 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 141:366249 CASREACT Full-text

TITLE . Preparation of pyrimidinone compounds as calcilytics INVENTOR(S): Shcherbakova, Irina V.; Balandrin,

Manuel F.; Buang, Guangfei;

Geoffroy, Otto; Foz, John; Marquis,

Robert; Yamashita, Dennis Shinji; Luengo, Juan; Wang,

Wenvong

PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA; Glaxosmithkline SOURCE:

PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent English LANGUAGE:

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092120	A2	20041028	WO 2004-US10638	20040407

```
WO 2004092120
                     A3 20050414
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
            LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
            NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
            TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
            BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
            ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
            SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
    AU 2004230903
                          20041028
                                          AU 2004-230903
                                                           20040407
                      A1
                         20041028
    CA 2521129
                      A1
                                          CA 2004-2521129 20040407
    EP 1615897
                          20060118
                                          EP 2004-749814 20040407
                      A2
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
    CN 1835928
                          20060920
                                          CN 2004-80009255 20040407
                      Α
    JP 2006522159
                      Τ
                           20060928
                                          JP 2006-509758
                                                          20040407
                                          MX 2005-PA10683 20051004
    MX 2005PA10683
                      Α
                           20060801
                                                           20061120
    US 2007197555
                      A1
                           20070823
                                          US 2006-552363
PRIORITY APPLN. INFO.:
                                          US 2003-460859P 20030407
                                          US 2003-479323P 20030618
                                          WO 2004-US10638 20040407
```

OTHER SOURCE(S): GI MARPAT 141:366249

AB Title compds. I [R1-2 = H, halo, CN, CF3, etc.; R3 = aryl; R4 = H, alkyl, etc.] are prepared For instance, 2-(2-Hydroxyphenyl)-6-methyl-3-phenethyl-3H-pyrimidin-4-one is prepared from o-hydroxybenzonitrile, acetyl chloride and Me acetoacetate. Compds. of the invention have IC50 values < 30 μM in a calcium receptor inhibition assay. I are useful for the treatment of abnormal bone or mineral homeostasis.

RX(5) OF 72 ...Q ===> P

5

```
RX(5) RCT Q 780771-39-3
          STAGE(1)
```

RGT S 1310-58-3 KOH SOL 7732-18-5 Water, 64-17-5 EtOH CON SUBSTAGE(1) overnight, reflux

SUBSTAGE(2) cooled

STAGE (2)

RGT K 7647-01-0 HC1 SOL 7732-18-5 Water

CON pH 1

PRO R 780771-35-9

REACTION SEAPCH

=> fil casre; d stat que 135; d stat que 140; s 135,140 not 130 FILE 'CASREACT' ENTERED AT 11:19:46 ON 13 DEC 2007 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT: 1840 - 8 Dec 2007 VOL 147 ISS 25

New CAS Information Use Policies, enter HELP USAGETERMS for details.

* CASREACT now has more than 13.8 million reactions * *

Some CASREACT records are derived from the ZIC/VINITI database (1974-1999) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compoiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

L7 STR



THIS STRUCTURE AS A PEACTANT/PEAGENT "NOT"-ed OUT OF ANSWER SET

NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 7

STEREO ATTRIBUTES: NONE






NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

*	* * * MAP	PINGS***			
NOD	SYM	ROL	NOD	SYM	ROL
3	N	PRO	12	N	RRT
12	N	RRT	3	N	PRO
T 1 1		CTD			




NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

*:	***MAPF	INGS****			
NOD	SYM	ROL	NOD	SYM	ROL
5	N	PRO	12	N	RRT
12	N	RRT	5	N	PRO
L12		ST	R		



NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

*** *MAPPINGS * * * *

NOD	SYM	ROL	NOD	SYM	ROL
3	N	PRO	16	N	RRT
16	N	RRT	3	N	PRO
1.13		STR			



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

*	***MAPP	INGS****			
NOD	SYM	ROL	NOD	SYM	ROL
5	N	PRO	16	N	RRT
16	N	RRT	5	N	PRO
L14		STR			



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

7.0	**MAPP	INGS****			
NOD	SYM	ROL	NOD	SYM	ROL
3 :	N	PRO	19	N	RRT
19	N	RRT	3	N	PRO
L15		ST	R		

Ak @24 Cy @28

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

****MAPPINGS****

NOD SYM ROL NOD SYM ROL 5 N PRO 19 N RRT 19 N RRT 5 N PRO

L18 1017 SEA FILE=CASREACT SSS FUL (L10 OR L11 OR L12 OR L13 OR L14 OR

L15) NOT L7 (7766 REACTIONS)

L31 STR

CH2~G5~Cy @25 26 27

VAR G1=H/X/CN/CF3/24/CB

VAR G2=16/17

REP G3=(1-3) C

VAR G4=H/24/25/28

REP G5=(0-1) CH2

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 24 DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 19

GGCAT IS UNS AT 21

GGCAT IS LOC AT 24

GGCAT IS UNS AT 27

GGCAT IS UNS AT 28

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 29

STEREO ATTRIBUTES: NONE

L35 13 SEA FILE=CASREACT SUB=L18 SSS FUL L31 (67 REACTIONS)

100.0% DONE 7766 VERIFIED 67 HIT RXNS 13 DOCS

SEARCH TIME: 00.00.01

L7 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 7

STEREO ATTRIBUTES: NONE





NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

*** * MAPPINGS * * * *

NOD	SYM	ROL	NOD	SYM	ROL
3	N	PRO	12	N	RRT
12	N	RRT	3	N	PRO
L11		STR			



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

* 1	* < - MAE	PRINGS * * * *			
NOD	SYM	ROL	NOD	SYM	ROL
5	N	PRO	12	N	RRI
12	N	RRT	5	N	PRC
112		CTD			



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

*	"""MAPPIN	33,44,4			
NOD	SYM	ROL	NOD	SYM	ROL
3	N	PRO	16	N	RRT
16	N	RRT	3	N	PRO
L13		STR			



NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

* 1	* * * MAPE	INGS+***			
NOD	SYM	ROL	NOD	SYM	ROL
5	N	PRO	16	N	RRT
16	N	RRT	5	N	PRO
L14		STE	₹		



NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

*	***MAPP	INGS***			
NOD	SYM	ROL	NOD	SYM	ROL
3	N	PRO	19	N	RRT
19	N	RRT	3	N	PRO
L15		ST	R		



NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

** * * * MAPPINGS * * * *

NOD SYM ROL NOD SYM ROL 5 N PRO 19 N RRT 19 N RRT 5 N PRO

L18 1017 SEA FILE=CASREACT SSS FUL (L10 OR L11 OR L12 OR L13 OR L14 OR L15) NOT L7 (7766 REACTIONS)

L37 STR

VAR G1=1/25/33

NODE ATTRIBUTES:

CONNECT IS E2 RC AT 12 CONNECT IS E1 RC AT 27

CONNECT IS E1 RC AT 37 CONNECT IS E1 RC AT 46

DEFAULT MLEVEL IS ATOM GGCAT IS UNS AT 12

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 48

STEREO ATTRIBUTES: NONE L40 4 SEA FILE

4 SEA FILE=CASREACT SUB=L18 SSS FUL L37 (13 REACTIONS)

100.0% DONE 87 VERIFIED 13 HIT RXNS

SEARCH TIME: 00.00.01

L46 10 (L35 OR L40) NOT L30

=> d ibib abs fhit 146 1-10; fil hom

 4 DOCS

TITLE: Preparation of pyrimidinones and quinazolinones as

calcilytic compounds

INVENTOR(S): Luengo, Juan I.; Marquis, Robert W., Jr.; Xie, Ren;

Yamashita, Dennis S.

PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

P	ATENT			KI	ND	DATE								DATE			
W	2005				1	2005	1117					S152		2005	0503		
	W:													BY,		CA,	CH,
														ES.			
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE.	KG,	KM,	KP,	KR,	KZ,
		LC,	LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,
		NI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,
		SM,	SY,	TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,
		ZM,	ZW														
	RW:	BW,	GH,	GM,	KE,	LS,	MW,	ΜZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,
		ΑZ,	ΒY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,
		EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	ΙE,	IS,	IT,	LT,	LU,	MC,	NL,	PL,	PT,
							BF,	ΒJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,
			ΝE,														
E	P 1742												-				
	R:													GB,			
														SK,		HR,	LV
-	S 2007				1	2007	1004		-					2006			
PRIORI	TY APP	LN.	INFO	. :					-					2004			
										20	05-U	S152:	24	2005	0503		
OTHER :	SOURCE	(S):			MAR	PAT	143:	4779	75								

AB The title compds. I [R1, R2 = H, halo, CN, etc.; or R1 and R2 may be bonded together to form a carbocyclic, heterocylic, aryl or heteroaryl ring; R3 = aryl or heteroaryl group which may have 1-5 substituents each selected from H, halo, CN, CF3, etc.; R4 = aryl which may have 1-3 substituents consisting of H, halo, CN, CF3, etc.; X = 0 or S1, useful for treating a disease or disorder characterized by an abnormal bone or mineral homeostasis, were prepared E.g., a multi-step synthesis of 2-(2-hydroxyphenyl)-3-(4-isopropylphenyl)-5,6,7,8-tetrahydro-3H-quinazolin- 4-one, starting from Et 2-aminocyclohex-1-enecarboxylate and 2-benzyloxybenzyl chloride, was given. The methods for treating diseases or disorders such as osteosarcoma, periodontal disease, fracture healing, osteoarthritis, joint replacement, rheumatoid arthritis, Paget's disease, humoral hypercalcemia, malignancy and osteoporosis by administering the compound I alone or in combination with anti-resorptive agents are disclosed.

RX(2) OF 83 ...F ===> G

$$\begin{array}{c|c} \lambda c & & \\$$

RX (2) RCT F 920264-52-4

STAGE (1)

RGT H 1310-58-3 KOH

SOL 7732-18-5 Water, 64-17-5 EtOH

CON SUBSTAGE(1) 5 hours, room temperature -> reflux

SUBSTAGE(2) reflux -> room temperature

STAGE (2)

RGT I 7647-01-0 HC1

SOL 7732-18-5 Water

CON room temperature, pH 1

PRO G 869564-58-9

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 2 OF 10 CASREACT COPYRIGHT 2007 ACS on STN

112:55906 CASREACT Full-text ACCESSION NUMBER:

TITLE: Process for preparing 4-hydroxypyrimidines as drug and

agrochemical intermediates

INVENTOR(S): Ataka, Kikuo; Omori, Kiyoshi PATENT ASSIGNEE(S): Ube Industries, Ltd., Japan

SOURCE: Eur. Pat. Appl., 10 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 326389	A2	19890802	EP 1989-300768	19890126
EP 326389	A3	19911113		
EP 326389	B1	19960911		
R: CH, DE,	FR, GB	, IT, LI		
JP 01279874	A	19891110	JP 1988-323436	19881223
JP 06025157	В	19940406		
US 4935516	A	19900619	US 1989-300612	19890123
PRIORITY APPLN. INFO			JP 1988-17239	19880129
OTHER SOURCE(S):	MA	RPAT 112:55906		
GI				

R1 R2 OH

AB The title compds. I (R1, R2 = H, C1-10 alkyl, C3-10 cycloalkyl, etc.; R3 = C7-10 alkyl, C3-10 cycloalkyl, etc.), useful as drug and agrochem. intermediates, were prepared by condensation of aminoalkenoates with amides. A mixture of Me 3-amino-2-pentenoate, HCONH2, and MeONa was heated for 3 h at 110° to give 91.9 mol% 6-ethyl-4-hydroxypyrimidine.

RX(4) OF 6 H + B ===> I

I YIELD 81%

RX(4) RCT H 55-21-0, B 124413-61-2 PRO I 83501-10-4 L46 ANSWER 3 OF 10 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 100:6431 CASREACT Full-text

TITLE: 1,3-Oxazines and related compounds. VI. Synthesis

and some reactions of 2,6-disubstited

4H-1,3-thiazin-4-ones

AUTHOR(S): Yamamoto, Yutaka; Ohnishi, Shuhei; Azuma, Yutaka

CORPORATE SOURCE: Tohoku Coll, Pharm., Sendai, 983, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1983), 31(6),

1929-35

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal LANGUAGE:

English

AB 2,6-Disubstituted 4H-1,3-thiazin-4-ones I (R = alkyl, Ph, pyridyl; R1 = alkyl, CH2Ph) were synthesized by successive treatment of RCONHCOCH2COR1 with acid, such as 70% HClO4 or FSO3H and H2S. Ammonolysis of I with NH3-EtOH gave the corresponding pyrimidin-4-ones; hydrolysis of 2-alkyl-1,3-thiazine derivs. yielded RCONHCOCH: CRISH reduction with NaBH4 or LiAlH4 afforded 3,4-dihydro-2H-1,3-thiazin-4-one derivs.

RX(62) OF 63 COMPOSED OF RX(26), RX(10) RX(62) BA ===> AE

BA

ΑE

RX (26) RCT BA 82437-55-6

RGT M 7783-06-4 H2S, H 497-19-8 Na2CO3, N 7789-21-1 HSO3F

STEPS

PRO Y 88136-80-5

CAT 144-55-8 NaHCO3

RCT Y 88136-80-5 RX(10)

RGT Q 1336-21-6 NH40H

PRO AE 55417-80-6

L46 ANSWER 4 OF 10 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 97:155925 CASREACT Full-text

Antiallergy agents. 2. 2-Pheny1-5-(1H-tetrazo1-5-TITLE: yl)pyrimidin-4(3H)-ones

AUTHOR(S): Juby, Peter F.; Hudyma, Thomas W.; Brown, Myron;

Essery, John M.; Partyka, Richard A.

CORPORATE SOURCE: Bristol Lab., Div. Bristol-Myers Co., Syracuse, NY,

13201, USA

Journal of Medicinal Chemistry (1982), 25(10), 1145-50 SOURCE:

CODEN: JMCMAR; ISSN: 0022-2623 DOCUMENT TYPE: Journal

LANGUAGE: English GI

ΑB I (R = alkoxy, OCH2CH:CH2, or cyclopropylmethoxy; R1 = H, OMe, NO2, NH2, or NMe2) were prepared and found to be about 5-10 times more potent than the corresponding pyrimidine-5-carboxylic acids when tested orally against passive cutaneous anaphylaxis in the rat. Structure-activity relations within the two series are similar. I (R = OPr, R1 = H) [64634-09-9] is in clin. trial for the prophylactic treatment of asthma.

RX(38) OF 80 BK ===> I...

RX (38) RCT BK 64634-07-7 PRO I 64661-66-1 SOL 67-68-5 DMSO

L46 ANSWER 5 OF 10 CASREACT COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 97:55759 CASREACT Full-text

TITLE: Studies on 1,3-benzoxazines. VII. Formation of

diphenylpyrimidines by the reaction of

4-chloro-2H-1,3-benzoxazines with ethyl

3-aminobutyrate

AUTHOR(S): Tachikawa, Ryuji; Wachi, Kazuyuki; Terada, Atsusuke CORPORATE SOURCE: SOURCE:

Cent. Res. Lab., Sankyo Co., Ltd., Tokyo, 140, Japan Chemical & Pharmaceutical Bulletin (1982), 30(2), 564-8

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: LANGUAGE: GI

Journal English

AB Treatment of chlorobenzoxazines I (R = Me, R1 = H, 5-MeO, 4-Cl, 5-Cl; R = Et, R1 = H; R = Ph, R1 = H) with H2NCHMeCH2CO2Et gave pyrimidine derivs. II. When 4-chloro-2-methyl-2-methoxycarbonylmethyl-2H-1,3-benzoxazine was treated with H2NCHMeCH2CO2Et, a pyrimidone derivative III was isolated. A possible mechanism for the formation of these reaction products is discussed.

RX(1) OF 5 ...A + B ===> C

RX(1) RCT A 82507-98-0, B 5303-65-1 PRO C 76467-22-6

L46 ANSWER 6 OF 10 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 95:24980 CASREACT Full-text

TITLE: Reaction of 3-aminocrotonamide with nitriles

AUTHOR(S): Kato, Tetsuzo; Chiba, Takuo; Sasaki, Makoto CORPORATE SOURCE: Pharm. Inst., Tohoku Univ., Sendai, 980, Japan

SOURCE: Heterocycles (1981), 16(4), 577-80

CODEN: HTCYAM; ISSN: 0385-5414

DOCUMENT TYPE: Journal LANGUAGE: English

0

AB Reaction of 3-aminocrotonamide with RCN (R = Me, Et, Me2CH, Ph) in MeOH in the presence of NaOMe gave I (same R) in 18-44% yields. Also, reaction of PhCH2CN with 3-aminocrotonamide gave 2-benzyl-6-methyl-4(3H)-pyrimidone and 6-amino-4-methyl-5-methyl-2(1H)-pyridone. Reaction of malononitrile with 3-aminocrotonamide gave 6-amino-5-cyano-4-methyl-2(1H)-pyridone.

RX(3) OF 7 A + G ===> H

RX(3) RCT A 15846-25-0, G 100-47-0 PRO H 13514-79-9

CAT 124-41-4 NaOMe

L46 ANSWER 7 OF 10 CASREACT COPYRIGHT 2007 ACS on STN ACCESSION NUMBER: 91:39426 CASREACT Full-text

TITLE: Synthetic plant growth regulators. The synthesis of

C-o-carboxyphenyl derivatives of pyrimidine

AUTHOR(S): Harris, Roger L. N.; Huppatz, John L.; Teitei, Tsutomu CORPORATE SOURCE: Div. Plant Ind., CSIRO, Canberra, 2601, Australia

CORPORATE SOURCE: Div. Plant Ind., CSIRO, Canberra, 2601, Australia
SOURCE: Australian Journal of Chemistry (1979), 32(3), 669-79

SOURCE: Australian Journal of Chemistry (1979), 32 CODEN: AJCHAS: ISSN: 0004-9425

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Synthetic routes to o-carboxyphenyl derivs. of pyrimidine, required for testing as potential plant growth regulators, are described. 2-(4-Phenylpyrimidin-2-yl)benzoic acid, 2-(2-phenylpyrimidin-4-yl)benzoic acid, and 2-(2-phenylpyrimidin-5-yl)benzoic acid were prepared by utilizing amide-acid chloride intermediates in the generation of the pyrimidine ring in each instance.

RX(34) OF 57 COMPOSED OF RX(10), RX(12) RX(34) R + S ===> U

U YIELD 25%

RX(10) RCT R 70484-37-6. S 611-74-5

PRO Q 70484-36-5

RX(12) RCT Q 70484-36-5

RGT K 10588-01-9 Na2Cr2O7

PRO U 343623-44-9

L46 ANSWER 8 OF 10 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 87:5899 CASREACT Full-text

TITLE: Pyrimidines. LIX. Ring transformations of

heterocyclic compounds with nucleophiles. Part XVI.
Degenerate ring transformations of

1,3-diethyl-1,4(3,4)-dihydro-4-oxopyrimidinium

tetrafluoroborates with ammonia

AUTHOR(S): Oostveen, E. A.; Van der Plas, H. C.

CORPORATE SOURCE: Lab. Org. Chem., Agric. Univ. Wageningen, Wageningen,

Netn.

SOURCE: Recueil des Travaux Chimiques des Pays-Bas (1977),

96(3), 68-72

CODEN: RTCPA3; ISSN: 0165-0513

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Treatment of the pyrimidinium tetrafluoroborates I (Rl = H, Me, Ph, OEt, R2 = H, Ph, Me) with aqueous NH3 or NH3(1) gave R2CONEtCOCH:CRINHEt (II) and EthHCOCH:CRINHEtCOR2 (III) via cleavage of the N(1)-C(2) or N(3)-C(2) bond, resp. However, in the case of I (Rl = OEt), II or III recyclized with NH3(1) with elimination of EtOH to give the ethylaminopyrimidinones IV.

RX(1) OF 17 ...A ===> B

RX (1) RCT A 343879-52-7 PRO B 62380-05-1 CAT 16872-11-0 HBF4

L46 ANSWER 9 OF 10 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 66:55438 CASREACT Full-text

TITLE: Reactions with trifluorochloroethylene, II. Addition

of trifluorochloroethylene to imidazole,

benzimidazole, and naphthimidazole -- a new cleavage of

the imidazole ring

AUTHOR(S): Ried, Walter; Lohwasser, Hermann

CORPORATE SOURCE: Univ. Frankfurt, Frankfurt, Germany

Justus Liebigs Annalen der Chemie (1966), 699, 88-97 SOURCE:

CODEN: JLACBF: ISSN: 0075-4617

DOCUMENT TYPE: Journal LANGUAGE: German

AB cf. CA 66, 28568c. The title compds. were alkylated on the N atom by CF2:CC1F

(I) under pressure at elevated temps, without a catalyst. The trifluorochloroethyl group makes the imidazole ring of the 1:1 adducts accessible to nucleophilic attack, which leads to a ring cleavage. A novel aldehyde synthesis and a triazole synthesis are described. The alkylations with I without catalyst proceeded in a few hrs. at temps. over 100° under the vapor pressure of the solution in absolute tetrahydrofuran (THF). Expts, with 10-80 q. compound were carried out in a 0.5-1 steel autoclave. Into the reaction chamber precooled with dry ice were introduced the intensely cooled solvent, the reacting compound with some hydroguinone, and the weighed liquefied I together with the cooling trap used for the condensation, in to bind the liberated HF from side reactions. On heating the autoclave, the pressure did not rise above 30 kg./cm.2 Benzimidazole (35 g.), 200 cc. THF, and 53 g. I heated 5 hrs. at 130-40° gave 61 g. N-(1,1,2-trifluoro-2chloroethyl)benzimidazole.

RX(3) OF 3 I + C ===> J

RX(3) RCT I 831-68-5, C 626-34-6

PRO J 13514-80-2

SOL 7732-18-5 Water

NTE Classification: Heterocycle formation; Condensation; Isomerisation; C-Amination; # Conditions: H2O 50-60 deg 2 days

L46 ANSWER 10 OF 10 CASREACT COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 51:39274 CASREACT Full-text

TITLE: Synthesis of 2,3,5,6-substituted 4-pyrimidones

AUTHOR(S): Staskun, Benjamin; Stephen, Henry

CORPORATE SOURCE: Univ. Witwatersrand Johannesburg, S. Afr.

SOURCE: Journal of the Chemical Society (1956) 4708-10 CODEN: JCSOA9; ISSN: 0368-1769

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB 2,3,5,6-Substituted 4-pyrimidones (I) were readily synthesized by condensation of imidovl chlorides (II) with Me or Et α -alkvl- θ - aminocrotonates (III). The following general procedure was used: II (0.01 mole) and III (0.005, 0.01, or 0.02 mole) were refluxed 3-4 hrs. in 40 cc. dry CHC13 (method A) or allowed to remain at room temperature 2-3 days (method B). In some cases II and III were heated in the absence of a solvent (method C), HCl and alc. being evolved. The products were acidified with dilute HCl and steam distilled; this hydrolyzed any unchanged ester to steam volatile or H2O soluble products, and converted unchanged II to the amide. After cooling, the latter was removed, and the filtrate treated with C and NH3 deposited crude I which crystallized from dilute MeOH or alc. in colorless needles. The following I were prepared by the above methods (R and R substituents in II (RCC1:NR'), R'' and X in III (MeC(NH2):CR''CO2X), molar ratio II:III, method, reaction temperature, reaction time in hrs., % yield, and m.p. given): Ph, Ph, Me, Me, 1:1, C, 140°, 0.5, -, -; Ph, Ph, Me, Et, 1:1, C, 140°, 0.5, 45, 157°; Ph, Ph, Et, Et, 1:2, A, -, 4, 79, 159°; Ph, o-C6H4Me, Me, Me, 1:1, A, -, 3, 53, 114°; Ph, o-C6H4Me, Et, Et, 1:2, A, -, 4, 80, 152°; Ph, m-C6H4Me, Me, Me, 1:1, C, 100°, 0.5, 31, 129°; Ph, m-C6H4Me, Me, Et, 1:1, C, 100°, 0.5, 28, -; Ph, m-C6H4Me, Et, Me, 1:1, C, 100°, 0.5, 77, 136°; Ph, m-C6H4Me, Et, Et, 1:2, A, -, 3, -, ; Ph. p-C6H4Me, Me, Me, 1:2, A, -, 3, 77, 146°; Ph. p-C6H4Me, Et. Et. 1:2, B. -, 3, 75, 152°; Ph, 2,4,1-Me2C6H3, Me, Me, 2:1, A, -, 3, 83, 152°; Ph, 2,4,1-Me2C6H3, Me, Et, 2:1, A, -, 3, -, -; Ph, 2,4,1-Me2C6H3, Et, Et, 2:1, A, -, 3, 83, 146°; Ph, p-MeOC6H4, Et, Et, 1:2, B, -, 3, 81, 161°; Ph, p-MeOC6H4, Pr, Me, 1:2, C, 155°, 0.5, 55, 163°; Ph, m-O2NC6H4, Me, Me, 1:2, C, 140°, 0.5, 62, 159°; Ph, m-O2NC6H4, Me, Et, 1:2, C, 140°, 0.5, 34, -; Ph, m-O2NC6H4, Et, Me, 1:2, C, 140°, 0.5, 24, 160°; Ph, m-O2NC6H4, Et, Et, 1:2, C, 140°, 0.5, 38, -; Ph, 1-C10H7, Me, Et, 1:2, A, -, 3, 64, 174°; Ph, 2-C10H7, Me, Et, 1:2, A, -, 3, 50, 189°; Ph, 2-C10H7, Et, Et, 1:2, A, -, 3, 40, 184°; Ph, o-C6H4Cl, Me, Et, 2:1, A, -, 3, 13, 151°; Ph, o-C6H4Cl, Et, Et, 2:1, C, 170°, 0.5, 32, 192°; Ph, m-C6H4Cl, Me, Me, 1:1, C, 150°, 0.5, 35, 152°; Ph, pC6H4Cl, Et, Et, 1:2, C, 185°, 0.5, 59, 148°; Ph, p-C6H4Cl, Pr, Me, 1:2, C, 185°, 0.5, 37, 154°; Ph, Et, Et, Et, 1:2, B, -, 3, 73, 82°; Ph, Et, Me, Et, 1:2, B, -, 3, 51, 118°; o-C6H4Me, Ph, Me, Me, 2:1, A, -, 3, 80, 112°; o-C6H4Me, Ph, Et, Et, 2:1, A, -, 3, 74, 137°; p-C6H4Cl, Ph, Et, Et, 1:2, C, 155°, 0.5, 67, 146°; p-C6H4Cl, Ph, Pr, Me, 1:2, C, 155°, 0.5, 21, 151°; 3,4,5-(MeO) 3C6H2, Ph, Me, Me, 1:2, A, -, 3, 20, 181°; 3,4,5-(MeO) 3C6H2, Ph, Et, Et, 1:2, A, -, 3, 37, 129°. The synthesis of I was modified by preparing II by rearrangement of ketoximes (IV) with PC15. The following procedures were used. A solution of IV (0.01 mole) in 50 cc. CHCl3 was treated at 0° with 0.01 mole PC15, the whole shaken 1-2 min., and the solution treated by one of the following procedures. The solution refluxed 15 min. to complete the rearrangement of IV, the III (0.02-0.03 mole) added in 10 cc. CHCl3, and reflux continued 2-3 hrs. (method D). Alternatively, the solution after remaining 2 hrs. at room temperature was cooled to 10°, the III (0.02-0.03 mole) in 10 cc. CHCl3 added, and the mixture left 1-2 days at room temperature (method E). The following method (F) gave good yields of I. The solution of rearranged IV, after 2 hrs. at room temperature was distilled at 40-5°/30 min., then stored 1-2 days with 0.02-0.03 mole III, and the products treated as previously described. I were crystallized as colorless needles from MeOH or alc. The following results were obtained (IV, R'' in III, method, % yield, and m.p. of I given): PhMeC:NOH, Et, E, 65, 126°; (p-MeC6H4)MeC:NOH, Et, E, 65, 82°; (p-MeC6H4)MeC:NOH, Me, D, 65, 146°; 2-C10H7CMe:NOH, Et, F, 65, 130°; PhPrc:NOH, Et, E, 72, 106°; PhPrc:NOH, Me, E, 35, 73°; (p-MeC6H4)2C:NOH, Me, F, 73, 128°; (p-MeC6H4)2C:NOH, Et, F, 60, 140°; Ph2C:NOH, Et, D, 55, 157°. Improved vields of I were obtained by using excess II or III.

RX(2) OF 2 D + E ===> F

VIELD 753

RX(2) RCT D 15999-95-8, E 42805-39-0

PRO F 110244-33-2

SOL 67-66-3 CHC13

NTE Classification: Heterocycle formation; Condensation; N-Acylation; # Conditions: CHCl3 20 deg 1-2days; # Comments: chloroimine reactant not isolated

SEARCH HISTORY

 \Longrightarrow d stat que 135; d stat que 140;d his nofile L7 $$\operatorname{STR}$$




NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 7

STEREO ATTRIBUTES: NONE



NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

+ :	AM*	PPINGS**	* *		
NOD	SYM	ROL	NOD	SYM	ROL
3	N	PRO	12	N	RRT
12	N	RRT	3	N	PRO
L11			STR		
BR	T		PRO)	




NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

*	* * * MAPP	INGS * * * *			
NOD	SYM	ROL	NOD	SYM	ROL
5	N	PRO	12	N	RRT
12	N	RRT	5	N	PRO
L12		STE	3		




NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

* :	***MAPP	INGS****			
NOD	SYM	ROL	NOD	SYM	ROL
3	N	PRO	16	N	RRT
16	N	RRT	3	N	PRO
L13		ST	R		



NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

14.5	CHATE, W. T.	1100			
NOD	SYM	ROL	NOD	SYM	ROL
5	N	PRO	16	N	RRT
16	N	RRT	5	N	PRO
T.14		STE	}		

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

*	***MAPP	INGS****			
NOD	SYM	ROL	NOD	SYM	ROL
3	N	PRO	19	N	RRT
19	N	RRT	3	N	PRO
L15		STR			



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

NOD SYM ROL NOD SYM PRO 19 N RRT 5 N 5 N RRT 19 N PRO

1017 SEA FILE=CASREACT SSS FUL (L10 OR L11 OR L12 OR L13 OR L14 OR L15) NOT L7 (7766 REACTIONS)

L31 STR

CH2-G5-Cy @25 26 27

VAR G1=H/X/CN/CF3/24/CB

VAR G2=16/17 REP G3=(1-3) C

VAR G4=H/24/25/28

REP G5=(0-1) CH2

NODE ATTRIBUTES: CONNECT IS E1 RC AT 24

DEFAULT MLEVEL IS ATOM GGCAT IS UNS AT 19

GGCAT IS UNS AT 21 GGCAT IS LOC AT 24 GGCAT IS UNS AT 27

GGCAT IS UNS AT 28
DEFAULT ECLEVEL IS LIMITED

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 29

STEREO ATTRIBUTES: NONE

L35 13 SEA FILE=CASREACT SUB=L18 SSS FUL L31 (67 REACTIONS)

100.0% DONE 7766 VERIFIED 67 HIT RXNS 13 DOCS SEARCH TIME: 00.00.01


L7 STR



NODE ATTRIBUTES: DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 7

STEREO ATTRIBUTES: NONE L10 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

*	* * MAPPI	MGS * * * *			
NOD	SYM	ROL	NOD	SYM	ROL
3	N	PRO	12	N	RRT
12	N	RRT	3	N	PRO
T.11		STE	2		



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

****MAPPINGS****

NOD SYM ROL NOD SYM ROL
5 N PRO 12 N RRT
12 N RRT 5 N PRO
L12 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

** * * MAPPINGS * * * *

NOD	SYM	ROL	NOD	SYM	ROL
3	N	PRO	16	N	RRT
16	N	RRT	3	N	PRO
T.13		CTI	D		



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

*	***MAPP	INGS****			
NOD	SYM	ROL	NOD	SYM	ROL
5	N	PRO	16	N	RRT
16	N	RRT	5	N	PRO
L14		STI	3		



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

****MAPPINGS****

NOD	SYM	ROL	NOD	SYM	ROL
3	N	PRO	19	N	RRT
19	N	RRT	3	N	PRO
1.15		STR			

315 SIK



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

****MAPPINGS****

NOD SYM ROL NOD SYM ROL 5 N PRO 19 N RRT 19 N RRT 5 N PRO

L18 1017 SEA FILE=CASREACT SSS FUL (L10 OR L11 OR L12 OR L13 OR L14 OR

L15) NOT L7 (7766 REACTIONS)

L37 STR

33

29

VAR GI=1/25/33
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 12
CONNECT IS E1 RC AT 27
CONNECT IS E1 RC AT 37
CONNECT IS E1 RC AT 46
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 12
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 48

STEREO ATTRIBUTES: NONE
L40 4 SEA FILE=CASREACT SUB=L18 SSS FUL L37 (13 REACTIONS)

100.0% DONE 87 VERIFIED 13 HIT RXNS 4 DOCS SEARCH TIME: 00.00.01

(FILE 'HOME' ENTERED AT 10:13:21 ON 13 DEC 2007)

FILE 'CAPLUS' ENTERED AT 10:13:35 ON 13 DEC 2007

E US2005-551920/APPS E US2006-551920/APPS

L1 1 SEA ABB=ON US2006-551920/AP D SCAN SEL RN

FILE 'REGISTRY' ENTERED AT 10:14:15 ON 13 DEC 2007

39 SEA ABB=ON (116046-53-8/BI OR 128095-14-7/BI OR 1583-88-6/BI OR 1655-07-8/BI OR 21615-34-9/BI OR 22396-14-1/BI OR 404-70-6/B I OR 51756-10-6/BI OR 25721-69-4/BI OR 5538-51-2/BI OR 607-97-6/BI OR 609-14-3/BI OR 611-10-9/BI OR 64-04-0/BI OR 780771-35-9/BI OR 780771-36-0/BI OR 780771-37-1/BI OR 780771-38-2/BI OR 780771-39-3/BI OR 780771-34-05-6/BI OR 780771-37-47/BI OR

780771-42-8/BI OR 780771-43-9/BI OR 780771-44-0/BI OR 780771-46-1/BI OR 780771-47-3/BI OR 780771-47-3/BI OR 780771-48-4/BI OR 780771-49-5/BI OR 780771-50-8/BI OR 780771-51-9/BI OR 780771-52-0/BI OR 780771-54-2/BI OR 780771-55-3/BI OR 780771-56-4/BI OR 780771-57/BI OR 780771-56-4/BI OR 780771-57/BI OR 780771-58-6/BI OR 780771-58-6/BI OR 780771-57/BI OR 780771-58-6/BI OR 780771-57/BI OR 780771-58-6/BI OR 780771-57/BI OR 780771-58-6/BI OR 780771-57/BI OR 780771-58-6/BI OR 780771-58-8-1/BI OR 780771-58-6/BI OR 780771-58-6/BI OR 780771-58-8-1/BI OR 780771-58-6/BI OR 780771-58-8-1/BI OR 780771-58-6/BI OR 780771-58-8-1/BI OR 780771-58-1/BI OR 780771-58-

```
FILE 'STNGUIDE' ENTERED AT 10:19:14 ON 13 DEC 2007
    FILE 'REGISTRY' ENTERED AT 10:34:32 ON 13 DEC 2007
T. 3
               STR
L4
             50 SEA SSS SAM L3
    FILE 'CASREACT' ENTERED AT 10:35:14 ON 13 DEC 2007
L5
               STR L3
1.6
             18 SEA SSS SAM L5 ( 274 REACTIONS)
L7
               STR L3
L8
             10 SEA SSS SAM L5 NOT L7 ( 161 REACTIONS)
               D OUE
1.9
               STR L5
L10
               STR L5
L11
               STR L10
L12
               STR L5
L13
               STR L12
L14
               STR L5
L15
               STR L14
L16
             5 SEA SSS SAM (L10 OR L11 OR L12 OR L13 OR L14 OR L15) NOT L7 (
                 18 REACTIONS)
               D OUE
         22744 SEA SSS FUL (L10 OR L11 OR L12 OR L13 OR L14 OR L15) NOT L7
L17
               (419109 REACTIONS) EXTEND
L18
          1017 SEA SSS FUL (L10 OR L11 OR L12 OR L13 OR L14 OR L15) NOT L7 (
               7766 REACTIONS)
               SAVE TEMP JAI920CASRE/A L18
           957 SEA ABB=ON L18/COMPLETE
L19
               SAVE TEMP L19 JAI920CASRE2/A
L20
             0 SEA ABB=ON US2006-551920/AP
L21
            29 SEA ABB=ON SHCHERBAKOVA I?/AU
             0 SEA ABB=ON BALANDRIA M?/AU
L22
L23
           101 SEA ABB=ON HUANG G?/AU
L24
             5 SEA ABB=ON GEOFFROY O?/AU
L25
           116 SEA ABB=ON FOX J?/AU
L26
            50 SEA ABB=ON NAIR S?/AU
L27
             3 SEA ABB=ON (L21 OR L22 OR L23 OR L24 OR L25 OR L26) AND L19
               D SCAN TI
L28
             1 SEA ABB=ON TETRASUB?/TI AND L27
               D BTBT
L29
             7 SEA ABB=ON BALANDRIN M?/AU
L30
             3 SEA ABB=ON (L21 OR L22 OR L23 OR L24 OR L25 OR L26 OR L29)
               AND L19
T.31
               STR
L32
             0 SEA SUB=L19 SSS SAM L31 (
                                            0 REACTIONS)
             0 SEA SUB=L19 SSS SAM L31 ( 0 REACTIONS)
L33
L34
          1017 SEA SUB=L18 SSS FUL L31 ( 7766 REACTIONS) EXTEND
            13 SEA SUB=L18 SSS FUL L31 ( 67 REACTIONS)
L35
               SAVE TEMP L35 JAI920CASRE3/A
L36
             3 SEA ABB=ON L35 AND L30
```

FILE 'STNGUIDE' ENTERED AT 10:56:32 ON 13 DEC 2007

FILE 'REGISTRY' ENTERED AT 11:05:59 ON 13 DEC 2007

FILE 'CASREACT' ENTERED AT 11:06:02 ON 13 DEC 2007 L37 $$\operatorname{STR}$$

L38 0 SEA SUB-L18 SSS SAM L37 (0 REACTIONS)
L39 17 SEA SUB-L18 SSS FUL L37 (87 REACTIONS) EXTEND
L40 4 SEA SUB-L18 SSS FUL L37 (13 REACTIONS)

SAVE TEMP L40 JAI920CASRE4/A

L41 13 SEA ABB=ON (L35 OR L40) L42 3 SEA ABB=ON L30 AND L40

L42 3 SEA ABB=ON L30 AND L40
L43 720 SEA ABB=ON L19 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'STNGUIDE' ENTERED AT 11:15:58 ON 13 DEC 2007

FILE 'CASREACT' ENTERED AT 11:18:27 ON 13 DEC 2007

L44 10 SEA ABB=ON L41 NOT L30 L45 9 SEA ABB=ON L44 AND L43

FILE 'CASREACT' ENTERED AT 11:19:12 ON 13 DEC 2007

D QUE NOS L30 D IBIB ABS FHIT L30 1-3

FILE 'CASREACT' ENTERED AT 11:19:46 ON 13 DEC 2007

D STAT QUE L35 D STAT QUE L40

L46 10 SEA ABB=ON (L35 OR L40) NOT L30

D IBIB ABS FHIT L46 1-10

FILE 'HOME' ENTERED AT 11:20:11 ON 13 DEC 2007

D STAT QUE L35

D STAT QUE L40

=>